Loading organizations...
§ Private Profile · San Diego, CA, USA
Otonomy is a technology company.
Otonomy was a biopharmaceutical company dedicated to developing innovative therapies for inner and middle ear disorders. It utilized specialized drug delivery platforms to treat conditions including Meniere's disease, hearing loss, and tinnitus. Its pipeline included candidates like OTO-104, OTO-413, and OTO-510, directly targeting auditory and vestibular systems for unmet medical needs.
Founded in 2008 by Jay Lichter, Allen F. Ryan, and Jeffrey Harris, Otonomy arose from recognizing unmet needs in ear-related pharmaceutical innovation. Founders, leveraging biotechnology and otolaryngology expertise, pioneered localized drug delivery. This approach enhanced therapeutic efficacy within sensitive ear structures, minimizing systemic side effects.
Otonomy aimed to benefit patients suffering from chronic and acute hearing and balance disorders. Its vision was to lead in neurotology by commercializing novel therapeutics that improve patient quality of life. Though Otonomy's operations concluded, its foundational work continues to inform specialized ear disorder treatment development.
Otonomy has raised $144.0M across 4 funding rounds.
Otonomy has raised $144.0M in total across 4 funding rounds.
I need to clarify an important factual correction: Otonomy is not a technology company—it is a biopharmaceutical company, and according to available information, it ceased operations in March 2023.
Otonomy, Inc. was a biopharmaceutical company dedicated to developing innovative therapeutics for neurotology, the medical field focused on diseases and disorders of the ear[1][2]. Rather than a traditional technology firm, Otonomy pioneered the application of drug delivery technology to the ear, enabling sustained drug exposure from a single local administration[1]. The company focused on addressing unmet medical needs in hearing loss and tinnitus through a pipeline of therapeutic candidates[1].
As of March 28, 2023, Otonomy went out of business[3], marking the end of its operations before achieving commercial success with any of its primary product candidates.
Otonomy's competitive positioning centered on its specialized approach to ear therapeutics:
At the time of its 2022 update, Otonomy had multiple programs in clinical development, with Phase 2 trial readouts expected for OTO-413 in hearing loss and OTO-313 in tinnitus[1]. However, the company's capital runway extended only into the second half of 2023[1], which ultimately proved insufficient to sustain operations through successful commercialization.
The company's closure represents a common outcome in biopharmaceutical development, where even promising therapeutic candidates may not reach market due to funding constraints, clinical trial outcomes, or competitive pressures.
Otonomy has raised $144.0M across 4 funding rounds. Most recently, it raised $49.0M Series D in April 2014.
Otonomy has raised $144.0M in total across 4 funding rounds.
Otonomy's investors include Avalon Ventures, Domain Associates, InterWest, Meritech Capital Partners, Ed Mathers, OrbiMed, Osage University Partners, Pivotal bioVenture Partners, RiverVest, Versant Ventures, Wildcat Ventures, Heather Preston.